Durvalumab After Chemoradiotherapy In Stage Iii Nsclc: 4-Year Survival Update From The Phase Iii Pacific TrialC. Faivre-Finn,D. Vicente,T. Kurata,D. Planchard,L. Paz-Ares,J. F. Vansteenkiste,D. R. Spigel,M. C. Garassino,M. Reck,S. Senan,J. Naidoo,A. Rimner,Y-L. Wu,J. E. Gray,M. Ozguroglu,K. H. Lee,M. Newton,L. Wang,P. Thiyagarajah,S. J. AntoniaAnnals of Oncology(2020)引用 44|浏览35暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要